Investigating how a coronavirus protein affects the export of mRNA from the nucleus
mRNA Nuclear Export Machinery as Target of SARS-CoV-2 Nsp1 Protein
This study is looking at how the COVID-19 virus uses a special protein to stop our cells from sending out important messages that help fight the virus, and it's for anyone interested in understanding how we might develop new treatments to combat COVID-19.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-11127764 on NIH RePORTER |
What this research studies
This research focuses on understanding how the SARS-CoV-2 virus, responsible for COVID-19, uses a specific protein called Nsp1 to inhibit the export of mRNA from the nucleus of host cells. By blocking this export, the virus can suppress the host's antiviral responses, making it easier for the virus to replicate. The researchers aim to explore the mechanisms behind this interaction and how mutations in the Nsp1 protein can affect its ability to inhibit mRNA export. This work combines expertise in biochemistry, cell biology, and viral pathogenesis to develop potential antiviral strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals affected by COVID-19 or those at high risk of severe outcomes from the virus.
Not a fit: Patients who are not infected with SARS-CoV-2 or those who have already recovered from COVID-19 may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new antiviral therapies that enhance the host's ability to fight off SARS-CoV-2 and potentially other viruses.
How similar studies have performed: Other research has shown promising results in targeting viral mechanisms to enhance antiviral responses, indicating that this approach has potential for success.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Ren, Yi — Vanderbilt University
- Study coordinator: Ren, Yi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.